Quick Takeaways:
- The FDA has issued an Emergency Use Authorization (EUA) for Capstar (nitenpyram) and revised the EUA for generic Nitenpyram Tablets to allow prevention and treatment of New World screwworm (NWS) infestations in dogs and cats weighing ≥2 lb and aged ≥4 weeks.
- The authorization addresses a previous gap, as earlier products were authorized for treatment but not prevention. Both products are available over the counter in 11.4 mg and 57 mg tablets, with dosing based on the pet’s weight.
- The FDA concluded that available evidence supports potential effectiveness and that the products’ benefits outweigh known and potential risks when used as authorized. Capstar is sponsored by Sergeant’s Pet Care Products, while generic Nitenpyram is sponsored by Felix Pharmaceuticals.
Why It Matters?
The FDA’s new and revised Emergency Use Authorizations for Capstar (nitenpyram) and generic nitenpyram tablets close a key gap by allowing both prevention and treatment of New World screwworm in dogs and cats, expanding the toolkit available to veterinarians and pet owners in affected or at‑risk areas. Because these products are over the counter and already widely used for fleas, the change can increase uptake for screwworm protection, support earlier and more consistent use in high‑risk regions, and strengthen the position of nitenpyram-based products alongside other authorized options in the companion-animal parasiticide market.
Source: Globenewswire
